Linagliptin (BioDeep_00000399108)
natural product
代谢物信息卡片
Linagliptin (BI-1356)
化学式: C25H28N8O2 (472.2335108)
中文名称: 利格列汀
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CC=C2C(=C1)N=C(N=C2C)CN3C(N(C4=C(C3=O)N(C(=N4)N5C[C@@H](CCC5)N)CC#CC)C)=O
InChI: InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
描述信息
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
2 个代谢物同义名
数据库引用编号
11 个数据库交叉引用编号
- ChEBI: CHEBI:68610
- KEGGdrug: D09566
- PubChem: 10096344
- DrugBank: DB08882
- ChEMBL: CHEMBL237500
- MeSH: Linagliptin
- CAS: 1233245-11-8
- CAS: 668270-12-0
- MoNA: CCMSLIB00000078546
- MoNA: CCMSLIB00000078545
- MoNA: CCMSLIB00000078544
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Nitin J Deshmukh, M S Kalshetti, Mohan Patil, Pankaj Autade, Ganesh V Sangle. Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1.
Clinical and experimental pharmacology & physiology.
2024 05; 51(5):e13854. doi:
10.1111/1440-1681.13854. [PMID: 38527859] - Aleksandra Liana, Adam Hałuszczuk, Andrzej Gawor, Ewa Bulska. Identification and Structural Characterization of Degradation Products of Linagliptin by Mass Spectrometry Techniques.
International journal of molecular sciences.
2024 Feb; 25(5):. doi:
10.3390/ijms25052591. [PMID: 38473837] - Anil Kumar Goud Thallapalli, Ram Mohan Manda. Development and validation of Empagliflozin and Linagliptin simultaneous estimation in rat plasma using freezing lipid precipitation and SCX-SPE assisted HPLC-MS/MS method and its application in pharmacokinetic studies.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.
2024 Jan; 40(1):185-198. doi:
10.1007/s44211-023-00444-z. [PMID: 37921942] - L Wan, Y Qian, W Ni, Y Lu, W Li, Y Pan, W Chen. [Linagliptin improves diabetic kidney disease in rats by promoting mitochondrial biogenesis through the AMPK/PGC-1α/TFAM pathway].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
2023 Dec; 43(12):2053-2060. doi:
10.12122/j.issn.1673-4254.2023.12.09. [PMID: 38189391] - Batool Zamani, Seyyed Mashaalah Tabatabizadeh, Hamidreza Gilasi, Shadi Yazdani. Effects of pioglitazone and linagliptin on glycemic control, lipid profile and hs-CRP in metformin-treated patients with type 2 diabetes: a comparative study.
Hormone molecular biology and clinical investigation.
2023 Dec; 44(4):385-391. doi:
10.1515/hmbci-2022-0070. [PMID: 38143260] - Mozhgan Karimifar, Jamileh Afsar, Massoud Amini, Firouzeh Moeinzadeh, Awat Feizi, Ashraf Aminorroaya. The effect of linagliptin on microalbuminuria in patients with diabetic nephropathy: a randomized, double blinded clinical trial.
Scientific reports.
2023 03; 13(1):3479. doi:
10.1038/s41598-023-30643-7. [PMID: 36859710] - Flavia Maria Silva-Veiga, Carolline Santos Miranda, Isabela Macedo Lopes Vasques-Monteiro, Henrique Souza-Tavares, Fabiane Ferreira Martins, Julio Beltrame Daleprane, Vanessa Souza-Mello. Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice.
World journal of gastroenterology.
2022 May; 28(17):1814-1829. doi:
10.3748/wjg.v28.i17.1814. [PMID: 35633911] - Kiran Khaladkar, Brij Mohan, Kiran Khaladkar, Sachin Suryawanshi, Hanmant Barkatestrong/Strong. Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study.
The Journal of the Association of Physicians of India.
2022 Apr; 70(4):11-12. doi:
NULL. [PMID: 35443373] - Mohammad Mehmandoust, Nevin Erk, Ceren Karaman, Onur Karaman. An electrochemical molecularly imprinted sensor based on CuBi2O4/rGO@MoS2 nanocomposite and its utilization for highly selective and sensitive for linagliptin assay.
Chemosphere.
2022 Mar; 291(Pt 1):132807. doi:
10.1016/j.chemosphere.2021.132807. [PMID: 34762887] - Jinsheng Lin, Feifei Chen, Chaohua Bao, Jian Ma, Dan Li, Lewei Zheng, Wenquan Zhu, Wenbin Chen, Xiaoming Liu. Investigation of an artificial solution degradant of linagliptin: An undesired linagliptin urea derivative generates in sample preparation of linagliptin tablet treated by sonication in acetonitrile containing diluent.
Journal of pharmaceutical and biomedical analysis.
2022 Feb; 210(?):114540. doi:
10.1016/j.jpba.2021.114540. [PMID: 34954487] - Josep Franch-Nadal, Jordi Real Gatius, Manel Mata-Cases, Emilio Ortega, Joan-Anton Valles, Bogdan Vlacho, Didac Mauricio. Compliance with the DPP-4 inhibitors dose adjustment recommendations based on renal function in a population database.
Endocrinologia, diabetes y nutricion.
2022 Feb; 69(2):83-91. doi:
10.1016/j.endien.2022.02.011. [PMID: 35256063] - Rodolfo Guardado-Mendoza, Miguel Angel Garcia-Magaña, Liz Jovanna Martínez-Navarro, Hilda Elizabeth Macías-Cervantes, Rodolfo Aguilar-Guerrero, Erick L Suárez-Pérez, Alberto Aguilar-García. Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection.
Scientific reports.
2022 01; 12(1):536. doi:
10.1038/s41598-021-04511-1. [PMID: 35017617] - Qizhi Tang, Weiyu Pan, Liangyue Peng. The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis.
Frontiers in endocrinology.
2022; 13(?):962385. doi:
10.3389/fendo.2022.962385. [PMID: 36060938] - Marcel H A Muskiet, Lennart Tonneijck, Mark M Smits, Mark H H Kramer, D Margriet Ouwens, Bolette Hartmann, Jens J Holst, A H Jan Danser, Jaap A Joles, Daniël H van Raalte. Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.
Diabetes, obesity & metabolism.
2022 01; 24(1):115-124. doi:
10.1111/dom.14557. [PMID: 34580975] - Panke Zhang, Jingxi Meng, Mingliang Duan, Dan Li, Ruixin Wang. Efficacy of Yishen Huashi Granules Combined with Linagliptin Tablets on Blood Glucose and Renal Function in Patients with Type 2 Diabetic Nephropathy.
Computational intelligence and neuroscience.
2022; 2022(?):4272520. doi:
10.1155/2022/4272520. [PMID: 36177313] - Angela Dardano, Michele Aragona, Giuseppe Daniele, Roberto Miccoli, Stefano Del Prato. Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.
Frontiers in endocrinology.
2022; 13(?):847778. doi:
10.3389/fendo.2022.847778. [PMID: 35295985] - Santenna Chenchula, Shoban Babu Varthya, R Padmavathi. Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies.
Current diabetes reviews.
2022; 18(4):e100921196392. doi:
10.2174/1573399817666210910165402. [PMID: 34514991] - Tsung-Jui Wu, Yi-Jen Hsieh, Chia-Wen Lu, Chung-Jen Lee, Bang-Gee Hsu. Linagliptin Protects against Endotoxin-Induced Acute Kidney Injury in Rats by Decreasing Inflammatory Cytokines and Reactive Oxygen Species.
International journal of molecular sciences.
2021 Oct; 22(20):. doi:
10.3390/ijms222011190. [PMID: 34681847] - Christian Ott, Susanne Jung, Manuel Korn, Dennis Kannenkeril, Agnes Bosch, Julie Kolwelter, Kristina Striepe, Peter Bramlage, Mario Schiffer, Roland E Schmieder. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
Cardiovascular diabetology.
2021 09; 20(1):178. doi:
10.1186/s12933-021-01358-8. [PMID: 34481498] - Firoozeh Moeinzadeh, Bijan Iraj, Mojgan Mortazavi, Pouria Ramezani. The Renoprotective Effect of Linagliptin in Type 2 Diabetic Patients with Severely Increased Albuminuria.
Iranian journal of kidney diseases.
2021 Sep; 15(5):344-350. doi:
NULL. [PMID: 34582369] - Nizar Attallah, Lina Yassine. Linagliptin in the Management of Type 2 Diabetes Mellitus After Kidney Transplant.
Transplantation proceedings.
2021 Sep; 53(7):2234-2237. doi:
10.1016/j.transproceed.2021.07.035. [PMID: 34376312] - Thomas Klein, Harald Tammen, Michael Mark, Elisa Benetti, Denis Delić, Cornelia Schepers, Maximilian von Eynatten. Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes.
Diabetes, obesity & metabolism.
2021 08; 23(8):1968-1972. doi:
10.1111/dom.14407. [PMID: 33881796] - Pranav Shah, Kejal Chavda, Bhavin Vyas, Shailaja Patel. Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition.
Drug delivery and translational research.
2021 06; 11(3):1166-1185. doi:
10.1007/s13346-020-00839-9. [PMID: 32804301] - Hany H Arab, Ahmed H Eid, Ayman M Mahmoud, Mahmoud A Senousy. Linagliptin mitigates experimental inflammatory bowel disease in rats by targeting inflammatory and redox signaling.
Life sciences.
2021 May; 273(?):119295. doi:
10.1016/j.lfs.2021.119295. [PMID: 33667522] - Herbert Nar, Gisela Schnapp, Oliver Hucke, Timothy C Hardman, Thomas Klein. Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
ChemMedChem.
2021 05; 16(9):1425-1426. doi:
10.1002/cmdc.202000921. [PMID: 33348462] - S-C Liu, C-C Lee, S-M Chuang, F-J Sun, Y-H Zeng. Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study.
Diabetes & metabolism.
2021 05; 47(3):101184. doi:
10.1016/j.diabet.2020.08.001. [PMID: 32827752] - Manal S Elmasry, Mohamed A Hasan, Wafaa S Hassan, Hanan A Merey, Israa M Nour. Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2021 Mar; 248(?):119258. doi:
10.1016/j.saa.2020.119258. [PMID: 33310272] - Tomoyuki Katsuno, Toshihiko Shiraiwa, Shingo Iwasaki, Hyohun Park, Nobuaki Watanabe, Shizuka Kaneko, Jungo Terasaki, Toshiaki Hanafusa, Akihisa Imagawa, Iichiro Shimomura, Hiroshi Ikegami, Hidenori Koyama, Mitsuyoshi Namba, Jun-Ichiro Miyagawa. Benefit of Early Add-on of Linagliptin to Insulin in Japanese Patients With Type 2 Diabetes Mellitus: Randomized-Controlled Open-Label Trial (TRUST2).
Advances in therapy.
2021 03; 38(3):1514-1535. doi:
10.1007/s12325-021-01631-y. [PMID: 33507500] - Wenying Yang, Xiangjin Xu, Tao Lei, Jianhua Ma, Ling Li, Jie Shen, Binqi Ye, Sandy Zhu, Thomas Meinicke. Efficacy and safety of linagliptin as add-on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
Diabetes, obesity & metabolism.
2021 02; 23(2):642-647. doi:
10.1111/dom.14231. [PMID: 33074590] - Anna-Lena Mayer, Iris Scheitacker, Nadja Ebert, Thomas Klein, Kerstin Amann, Christoph Daniel. The dipeptidyl peptidase 4 inhibitor linagliptin ameliorates renal injury and accelerated resolution in a rat model of crescentic nephritis.
British journal of pharmacology.
2021 02; 178(4):878-895. doi:
10.1111/bph.15320. [PMID: 33171531] - Ahmed A Gahlan, Ahmed M Haredy, Sayed M Derayea, Mahmoud A Omar, Gamal A Saleh. A Glassy Carbon Electrode for the Determination of Linagliptin, an Antidiabetic Drug in Pure Form, Tablets and Some Biological Fluids by Adsorptive Stripping Voltammetry.
Current pharmaceutical design.
2021; 27(20):2415-2424. doi:
10.2174/1381612826666200925123245. [PMID: 32981495] - Ran Abuhasira, Irit Ayalon-Dangur, Neta Zaslavsky, Ronit Koren, Mally Keller, Dror Dicker, Alon Grossman. A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19.
Frontiers in endocrinology.
2021; 12(?):794382. doi:
10.3389/fendo.2021.794382. [PMID: 35002970] - Rania A Elrashidy, Rehab A Hasan. Stromal cell-derived factor-1α predominantly mediates the ameliorative effect of linagliptin against cisplatin-induced testicular injury in adult male rats.
Cytokine.
2020 12; 136(?):155260. doi:
10.1016/j.cyto.2020.155260. [PMID: 32892071] - Junkichi Kanda, Megumi Furukawa, Nobuo Izumo, Taketoshi Shimakura, Noriaki Yamamoto, Hideaki E Takahashi, Hiroyuki Wakabayashi. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice.
Drug discoveries & therapeutics.
2020 Nov; 14(5):218-225. doi:
10.5582/ddt.2020.03073. [PMID: 33116039] - Marcel H A Muskiet, Lennart Tonneijck, Mark M Smits, Mark H H Kramer, D Margriet Ouwens, Bolette Hartmann, Jens J Holst, Daan J Touw, A H Jan Danser, Jaap A Joles, Daniël H van Raalte. Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
Diabetes care.
2020 11; 43(11):2889-2893. doi:
10.2337/dc20-0902. [PMID: 32900785] - Ali Ihsan Yagoglu, Oguzhan Sıtkı Dizdar, Selahattin Erdem, Berkan Akcakaya, Ali Ihsan Gunal. The effect of linagliptin on renal progression in type-2 diabetes mellitus patients with chronic kidney disease: A prospective randomized controlled study.
Nefrologia.
2020 Nov; 40(6):664-671. doi:
10.1016/j.nefro.2020.04.023. [PMID: 32736891] - Nan Wu, Guohua An. Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human.
The AAPS journal.
2020 09; 22(6):125. doi:
10.1208/s12248-020-00481-w. [PMID: 32996028] - Ahmed H Naggar, Gamal A Saleh, Mahmoud A Omar, Ahmed M Haredy, Sayed M Derayea. Square-wave Adsorptive Anodic Stripping Voltammetric Determination of Antidiabetic Drug Linagliptin in Pharmaceutical Formulations and Biological Fluids Using a Pencil Graphite Electrode.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.
2020 Sep; 36(9):1031-1038. doi:
10.2116/analsci.19p469. [PMID: 32062631] - Alexander S Christensen, Sofie Hædersdal, Julie Støy, Heidi Storgaard, Ulla Kampmann, Julie L Forman, Marta Seghieri, Jens J Holst, Torben Hansen, Filip K Knop, Tina Vilsbøll. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA).
Diabetes care.
2020 09; 43(9):2025-2033. doi:
10.2337/dc20-0408. [PMID: 32661107] - Yara M Aboulmagd, Alshaymaa A Z El-Bahy, Esther T Menze, Samar S Azab, Ebtehal El-Demerdash. Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats.
European journal of pharmacology.
2020 Aug; 881(?):173224. doi:
10.1016/j.ejphar.2020.173224. [PMID: 32454118] - Sri Nagarjun Batchu, Veera Ganesh Yerra, Youan Liu, Suzanne L Advani, Thomas Klein, Andrew Advani. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans.
International journal of molecular sciences.
2020 Aug; 21(16):. doi:
10.3390/ijms21165756. [PMID: 32796688] - Arata Hibi, Yuto Kasahara, Yoshitaka Ishihara, Koichi Hata, Norihisa Hosokawa, Takahiko Nakagawa. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
CEN case reports.
2020 08; 9(3):189-194. doi:
10.1007/s13730-020-00452-2. [PMID: 31993957] - Heba A Aref, Sherin F Hammad, Mohamed Saleh Elgawish, Khaled M Darwish. Novel spectrofluorimetric quantification of linagliptin in biological fluids exploiting its interaction with 4-chloro-7-nitrobenzofurazan.
Luminescence : the journal of biological and chemical luminescence.
2020 Aug; 35(5):626-635. doi:
10.1002/bio.3767. [PMID: 31919997] - Vlado Perkovic, Robert Toto, Mark E Cooper, Johannes F E Mann, Julio Rosenstock, Darren K McGuire, Steven E Kahn, Nikolaus Marx, John H Alexander, Bernard Zinman, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Maximillian von Eynatten, Jyothis T George, Odd Erik Johansen, Christoph Wanner. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
Diabetes care.
2020 08; 43(8):1803-1812. doi:
10.2337/dc20-0279. [PMID: 32444457] - Akiko Sarashina, Koji Chiba, Shinji Tatami, Yukio Kato. Physiologically Based Pharmacokinetic Model of the DPP-4 Inhibitor Linagliptin to Describe its Nonlinear Pharmacokinetics in Humans.
Journal of pharmaceutical sciences.
2020 07; 109(7):2336-2344. doi:
10.1016/j.xphs.2020.03.031. [PMID: 32283067] - Mark E Cooper, Julio Rosenstock, Takashi Kadowaki, Yutaka Seino, Christoph Wanner, Sven Schnaidt, Douglas Clark, Odd Erik Johansen. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial.
Diabetes, obesity & metabolism.
2020 07; 22(7):1062-1073. doi:
10.1111/dom.13995. [PMID: 32037653] - Hassan B Awal, Seshagiri Rao Nandula, Cleyton C Domingues, Fiona J Dore, Nabanita Kundu, Beda Brichacek, Mona Fakhri, Adrian Elzarki, Neeki Ahmadi, Shauna Safai, Magan Fosso, Richard L Amdur, Sabyasachi Sen. Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.
Cardiovascular diabetology.
2020 06; 19(1):72. doi:
10.1186/s12933-020-01046-z. [PMID: 32493344] - Niki Katsiki, Richard Ofori-Asenso, Ele Ferrannini, Mohsen Mazidi. Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Diabetes, obesity & metabolism.
2020 06; 22(6):1001-1005. doi:
10.1111/dom.13989. [PMID: 32020696] - F O Santos, B R O Correia, T S Marinho, Sandra Barbosa-da-Silva, Carlos A Mandarim-de-Lacerda, Vanessa Souza-Mello. Anti-steatotic linagliptin pleiotropic effects encompasses suppression of de novo lipogenesis and ER stress in high-fat-fed mice.
Molecular and cellular endocrinology.
2020 06; 509(?):110804. doi:
10.1016/j.mce.2020.110804. [PMID: 32259637] - Ildiko Lingvay, Nadine Beetz, Regina Sennewald, Annette Schuler-Metz, Julia Bertulis, Christina Loley, Benjamin Lang, Caroline Lippert, Jisoo Lee, Linda Shapiro Manning, Derek Terada. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
Postgraduate medicine.
2020 May; 132(4):337-345. doi:
10.1080/00325481.2020.1750228. [PMID: 32366156] - Robert Guthrie. Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.
Postgraduate medicine.
2020 May; 132(4):314-319. doi:
10.1080/00325481.2020.1742524. [PMID: 32164494] - Anton I Korbut, Iuliia S Taskaeva, Nataliya P Bgatova, Natalia A Muraleva, Nikolai B Orlov, Maksim V Dashkin, Anna S Khotskina, Evgenii L Zavyalov, Vladimir I Konenkov, Thomas Klein, Vadim V Klimontov. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes.
International journal of molecular sciences.
2020 Apr; 21(8):. doi:
10.3390/ijms21082987. [PMID: 32340263] - Yayoi Nishida, Yasuo Takahashi, Kotoe Tezuka, Hayato Akimoto, Tomohiro Nakayama, Satoshi Asai. Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
BMC pharmacology & toxicology.
2020 04; 21(1):28. doi:
10.1186/s40360-020-00407-4. [PMID: 32317005] - Akira Mima, Toshinori Yasuzawa, Tomomi Nakamura, Shigeru Ueshima. Linagliptin affects IRS1/Akt signaling and prevents high glucose-induced apoptosis in podocytes.
Scientific reports.
2020 04; 10(1):5775. doi:
10.1038/s41598-020-62579-7. [PMID: 32238837] - Marieke Sternkopf, Magdolna Nagy, Constance C F M J Baaten, Marijke J E Kuijpers, Bibian M E Tullemans, Julia Wirth, Wendy Theelen, Tom G Mastenbroek, Michael Lehrke, Benjamin Winnerling, Lesley Baerts, Nikolaus Marx, Ingrid De Meester, Yvonne Döring, Judith M E M Cosemans, Andreas Daiber, Sebastian Steven, Joachim Jankowski, Johan W M Heemskerk, Heidi Noels. Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.
Arteriosclerosis, thrombosis, and vascular biology.
2020 03; 40(3):e65-e77. doi:
10.1161/atvbaha.119.313645. [PMID: 31893947] - Rodolfo Guardado-Mendoza, Sara Stephania Salazar-López, Mildred Álvarez-Canales, Diana Farfán-Vázquez, Yoscelina Estrella Martínez-López, Lilia M Jiménez-Ceja, Erick L Suárez-Pérez, Fabiola Angulo-Romero, Maria Lola Evia-Viscarra, María Luisa Montes de Oca-Loyola, Edgar G Durán-Pérez, Franco Folli, Alberto Aguilar-García. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.
Metabolism: clinical and experimental.
2020 03; 104(?):154054. doi:
10.1016/j.metabol.2019.154054. [PMID: 31887309] - Denis Delić, Franziska Wiech, Richard Urquhart, Ogsen Gabrielyan, Kathrin Rieber, Marcel Rolser, Oleg Tsuprykov, Ahmed A Hasan, Bernhard K Krämer, Patrick Baum, Andreas Köhler, Florian Gantner, Michael Mark, Berthold Hocher, Thomas Klein. Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6 nephrectomy.
Scientific reports.
2020 02; 10(1):3373. doi:
10.1038/s41598-020-60336-4. [PMID: 32099009] - Feng Bai, Li-Hui Zhang, Wei-Wei Zhang, Rong-Hua Zheng, Joshua Robert Eskew, Josiah Bennett, Ning-Ping Wang, Himangshu S Bose, Zhi-Qing Zhao. Conservation of glucagon like peptide-1 level with liraglutide and linagilptin protects the kidney against angiotensin II-induced tissue fibrosis in rats.
European journal of pharmacology.
2020 Jan; 867(?):172844. doi:
10.1016/j.ejphar.2019.172844. [PMID: 31811859] - Woo Youl Kang, Hae Won Lee, Mi-Ri Gwon, Seungil Cho, Wang-Seob Shim, Kyung-Tae Lee, Dong Heon Yang, Sook Jin Seong, Young-Ran Yoon. A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers.
Drug design, development and therapy.
2020; 14(?):2101-2111. doi:
10.2147/dddt.s248205. [PMID: 32546973] - Makoto Ide, Noriyuki Sonoda, Tomoaki Inoue, Shinichiro Kimura, Yohei Minami, Hiroaki Makimura, Eiichi Hayashida, Fuminori Hyodo, Mayumi Yamato, Ryoichi Takayanagi, Toyoshi Inoguchi. The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation.
PloS one.
2020; 15(2):e0228750. doi:
10.1371/journal.pone.0228750. [PMID: 32032367] - Haoran Wang, Yue Li, Xiaoliang Zhang, Zhonglin Xu, Jianzhong Zhou, Wei Shang. DPP-4 Inhibitor Linagliptin Ameliorates Oxidized LDL-Induced THP-1 Macrophage Foam Cell Formation and Inflammation.
Drug design, development and therapy.
2020; 14(?):3929-3940. doi:
10.2147/dddt.s249846. [PMID: 33061298] - Mai M Helmy, Samar M Mouneir. Reno-protective effect of linagliptin against gentamycin nephrotoxicity in rats.
Pharmacological reports : PR.
2019 Dec; 71(6):1133-1139. doi:
10.1016/j.pharep.2019.06.017. [PMID: 31675669] - Mohamed Abouelkheir, Tarek H El-Metwally. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
European journal of pharmacology.
2019 Nov; 862(?):172638. doi:
10.1016/j.ejphar.2019.172638. [PMID: 31491403] - Khanda F M Amin, Ahmed M Abdullah, Nabil A Fakhre. Mean centering-triple divisor and ratio derivative-zero crossing for simultaneous determination of some diabetes drugs in their quaternary mixture with severely overlapping spectra.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2019 Nov; 222(?):117261. doi:
10.1016/j.saa.2019.117261. [PMID: 31228859] - Gilbert Ledesma, Guillermo E Umpierrez, John E Morley, Diane Lewis-D'Agostino, Annett Keller, Thomas Meinicke, Sandra van der Walt, Maximilian von Eynatten. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
Diabetes, obesity & metabolism.
2019 11; 21(11):2465-2473. doi:
10.1111/dom.13829. [PMID: 31297968] - Chelsea R Hutch, Karen Roelofs, April Haller, Joyce Sorrell, Kyle Leix, David D D'Alessio, Robert Augustin, Randy J Seeley, Thomas Klein, Darleen A Sandoval. The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice.
Diabetologia.
2019 10; 62(10):1928-1937. doi:
10.1007/s00125-019-4963-5. [PMID: 31414143] - Geert Jan Biessels, Chloë Verhagen, Jolien Janssen, Esther van den Berg, Bernard Zinman, Julio Rosenstock, Jyothis T George, Anna Passera, Sven Schnaidt, Odd Erik Johansen. Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial.
Diabetes care.
2019 10; 42(10):1930-1938. doi:
10.2337/dc19-0783. [PMID: 31399442] - Rodolfo Guardado-Mendoza, David Cázares-Sánchez, María Lola Evia-Viscarra, Lilia M Jiménez-Ceja, Edgar G Durán-Pérez, Alberto Aguilar-García. Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: A comparative study.
Diabetes research and clinical practice.
2019 Oct; 156(?):107864. doi:
10.1016/j.diabres.2019.107864. [PMID: 31539565] - Nordin Mj Hanssen, Karin Am Jandeleit-Dahm. Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?.
Diabetes & vascular disease research.
2019 07; 16(4):303-309. doi:
10.1177/1479164119842339. [PMID: 31018682] - Sara S Mourad, Eman I El-Kimary, Magda A Barary, Dalia A Hamdy. Pharmacokinetic interaction between linagliptin and tadalafil in healthy Egyptian males using a novel LC-MS method.
Bioanalysis.
2019 Jul; 11(14):1321-1336. doi:
10.4155/bio-2018-0097. [PMID: 31368774] - Munthaj Shaik, Swaroopa Rani Vanapatla. Enhanced oral bioavailability of linagliptin by the influence of gallic acid and ellagic acid in male Wistar albino rats: involvement of p-glycoprotein inhibition.
Drug metabolism and personalized therapy.
2019 06; 34(2):. doi:
10.1515/dmpt-2018-0020. [PMID: 31256062] - Angelo Del Parigi, Wenbo Tang, Dacheng Liu, Christopher Lee, Richard Pratley. Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data.
Pharmaceutical medicine.
2019 06; 33(3):209-217. doi:
10.1007/s40290-019-00281-4. [PMID: 31933292] - Ahmed A Hasan, Karoline von Websky, Christoph Reichetzeder, Oleg Tsuprykov, Mohamed M S Gaballa, Jingli Guo, Shufei Zeng, Denis Delić, Harald Tammen, Thomas Klein, Burkhard Kleuser, Berthold Hocher. Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy.
Kidney international.
2019 06; 95(6):1373-1388. doi:
10.1016/j.kint.2019.01.010. [PMID: 30979564] - Belén Sánchez López-Muelas, Salomé Muray Cases, Fátima Illán Gómez, Gloria García Guzmán, María Elena Arjonilla Sampedro. Bullous pemphigoid associated with linagliptin treatment in diabetic patients with chronic kidney disease.
Endocrinologia, diabetes y nutricion.
2019 May; 66(5):338-339. doi:
10.1016/j.endinu.2018.11.003. [PMID: 30630688] - Naruya Ishizue, Shinichi Niwano, Hiroe Niwano, Jun Oikawa, Hironori Nakamura, Takehiro Hashikata, Tazuru Igarashi, Tamami Fujiishi, Tomoharu Yoshizawa, Jun Kishihara, Akira Satoh, Hidehira Fukaya, Junya Ako. Linagliptin Suppresses Electrical and Structural Remodeling in the Isoproterenol Induced Myocardial Injury Model.
International heart journal.
2019 Mar; 60(2):411-418. doi:
10.1536/ihj.18-226. [PMID: 30745531] - Umakant Ashok Bahirat, Rashmi Talwar, Rekha Raghuveer Shenoy, Kumar V S Nemmani, Rajan Naresh Goel. Combination of APD668, a G protein-coupled receptor 119 agonist with linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in a murine model of non-alcoholic steatohepatitis with diabetes.
Medical molecular morphology.
2019 Mar; 52(1):36-43. doi:
10.1007/s00795-018-0200-4. [PMID: 29959534] - Seung Jung Kim, Soon Kil Kwon, Hye-Young Kim, Sun Moon Kim, Jang-Whan Bae, Joong-Kook Choi. DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction.
BMC nephrology.
2019 03; 20(1):75. doi:
10.1186/s12882-019-1243-z. [PMID: 30823876] - Justyna Siwy, Thomas Klein, Marcel Rosler, Maximilian von Eynatten. Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial.
Proteomics. Clinical applications.
2019 03; 13(2):e1800144. doi:
10.1002/prca.201800144. [PMID: 30632692] - Bahia Abbas Moussa, Marianne Alphonse Mahrouse, Michael Gamal Fawzy. A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers.
Journal of pharmaceutical and biomedical analysis.
2019 Jan; 163(?):153-161. doi:
10.1016/j.jpba.2018.09.052. [PMID: 30312887] - Darren K McGuire, John H Alexander, Odd Erik Johansen, Vlado Perkovic, Julio Rosenstock, Mark E Cooper, Christoph Wanner, Steven E Kahn, Robert D Toto, Bernard Zinman, David Baanstra, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Jyothis T George, Maximilian von Eynatten, Nikolaus Marx. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
Circulation.
2019 01; 139(3):351-361. doi:
10.1161/circulationaha.118.038352. [PMID: 30586723] - Mamdouh A Oraby, Mohammed F El-Yamany, Marwa M Safar, Naglaa Assaf, Hamdy A Ghoneim. Amelioration of Early Markers of Diabetic Nephropathy by Linagliptin in Fructose-Streptozotocin-Induced Type 2 Diabetic Rats.
Nephron.
2019; 141(4):273-286. doi:
10.1159/000495517. [PMID: 30699409] - Kohei Kaku, Masakazu Haneda, Yuko Tanaka, Ganghyuck Lee, Kosuke Shiki, Yuki Miyamoto, Fernando Solimando, Jisoo Lee, Christopher Lee, Jyothis George. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
Diabetes, obesity & metabolism.
2019 01; 21(1):136-145. doi:
10.1111/dom.13496. [PMID: 30091172] - Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner, Bernard Zinman, Hans Juergen Woerle, David Baanstra, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Jyothis T George, Maximilian von Eynatten, Darren K McGuire. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
JAMA.
2019 01; 321(1):69-79. doi:
10.1001/jama.2018.18269. [PMID: 30418475] - Ryuzo Kawamori, Masakazu Haneda, Keiko Suzaki, Gang Cheng, Kosuke Shiki, Yuki Miyamoto, Fernando Solimando, Christopher Lee, Jisoo Lee, Jyothis George. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
Diabetes, obesity & metabolism.
2018 09; 20(9):2200-2209. doi:
10.1111/dom.13352. [PMID: 29766636] - Gerd Luippold, Michael Mark, Thomas Klein, Kerstin Amann, Christoph Daniel. Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.
Diabetes research and clinical practice.
2018 Sep; 143(?):199-203. doi:
10.1016/j.diabres.2018.07.009. [PMID: 30031047] - Taku Koyama, Atsushi Tanaka, Hisako Yoshida, Jun-Ichi Oyama, Shigeru Toyoda, Masashi Sakuma, Teruo Inoue, Yoritaka Otsuka, Koichi Node. Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT).
Heart and vessels.
2018 Aug; 33(8):958-964. doi:
10.1007/s00380-018-1136-2. [PMID: 29427024] - Ralph A DeFronzo, Christopher Lee, Sven Kohler. Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.
Advances in therapy.
2018 Jul; 35(7):1009-1022. doi:
10.1007/s12325-018-0724-y. [PMID: 29949041] - Huan Huang, Sharash Shetty, Elise Bauer, Kathleen Lang. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
Current medical research and opinion.
2018 06; 34(6):1021-1027. doi:
10.1080/03007995.2017.1416346. [PMID: 29231750] - William V Tamborlane, Lori Mb Laffel, Jacques Weill, Maud Gordat, Dietmar Neubacher, Silke Retlich, Willem Hettema, Cornelia E Hoesl, Stefan Kaspers, Jan Marquard. Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes.
Pediatric diabetes.
2018 06; 19(4):640-648. doi:
10.1111/pedi.12616. [PMID: 29171139] - Fausto Chiazza, Harald Tammen, Hiranya Pintana, Grazyna Lietzau, Massimo Collino, Thomas Nyström, Thomas Klein, Vladimer Darsalia, Cesare Patrone. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
Cardiovascular diabetology.
2018 05; 17(1):60. doi:
10.1186/s12933-018-0702-3. [PMID: 29776406] - Norbert J Tripolt, Felix Aberer, Regina Riedl, Jasmin Url, Gudrun Dimsity, Andreas Meinitzer, Tatjana Stojakovic, Faisal Aziz, Ronald Hödl, Gabriele Brachtl, Dirk Strunk, Marianne Brodmann, Franz Hafner, Harald Sourij. Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
Cardiovascular diabetology.
2018 05; 17(1):71. doi:
10.1186/s12933-018-0716-x. [PMID: 29773079] - Rosemarie Lajara. The MARLINA-T2D trial: putting the results into clinical perspective.
Expert review of endocrinology & metabolism.
2018 05; 13(3):173-176. doi:
10.1080/17446651.2018.1455497. [PMID: 30058901] - Akira Kurozumi, Yosuke Okada, Hiroaki Satoh, Ikuo Inoue, Hiroko Chimori, Etsuko Akita, Toshihiko Shiraiwa, Yoshio Fujitani, Tomoya Mita, Masahiko Gosho, Hirotaka Watada. Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
Endocrine journal.
2018 Apr; 65(4):415-425. doi:
10.1507/endocrj.ej17-0386. [PMID: 29367471] - Julio Rosenstock, Vlado Perkovic, John H Alexander, Mark E Cooper, Nikolaus Marx, Michael J Pencina, Robert D Toto, Christoph Wanner, Bernard Zinman, David Baanstra, Egon Pfarr, Michaela Mattheus, Uli C Broedl, Hans-Juergen Woerle, Jyothis T George, Maximilian von Eynatten, Darren K McGuire. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
Cardiovascular diabetology.
2018 03; 17(1):39. doi:
10.1186/s12933-018-0682-3. [PMID: 29540217] - Keizo Kanasaki. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
Clinical science (London, England : 1979).
2018 02; 132(4):489-507. doi:
10.1042/cs20180031. [PMID: 29491123] - Sang Youb Han, Sun Ae Yoon, Byoung Geun Han, Sung Gyun Kim, Young-Il Jo, Kyung Hwan Jeong, Kook-Hwan Oh, Hyeong Cheon Park, Sun-Hee Park, Shin-Wook Kang, Ki-Ryang Na, Sun Woo Kang, Nam-Ho Kim, Younghwan Jang, Bogyeong Kim, Seonghye Shin, Dae Ryong Cha. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Diabetes, obesity & metabolism.
2018 02; 20(2):292-300. doi:
10.1111/dom.13059. [PMID: 28719008] - Chor Ho Jo, Sua Kim, Joon-Sung Park, Gheun-Ho Kim. Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy.
Kidney & blood pressure research.
2018; 43(3):987-999. doi:
10.1159/000490688. [PMID: 29913457] - Netanya Y Spencer, Zhihong Yang, Jensyn Cone Sullivan, Thomas Klein, Robert C Stanton. Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes.
PloS one.
2018; 13(7):e0200249. doi:
10.1371/journal.pone.0200249. [PMID: 29979777] - Sura Al Zoubi, Jianmin Chen, Catherine Murphy, Lukas Martin, Fausto Chiazza, Debora Collotta, Muhammad M Yaqoob, Massimo Collino, Christoph Thiemermann. Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB.
Frontiers in immunology.
2018; 9(?):2996. doi:
10.3389/fimmu.2018.02996. [PMID: 30619349]